No Data
No Data
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Fly 27% But Investors Aren't Buying For Growth
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley
Morgan Stanley Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $31
No Data
No Data